Nektar Therapeutics (NKTR) EBIAT (2016 - 2025)
Nektar Therapeutics (NKTR) has 16 years of EBIAT data on record, last reported at -$35.5 million in Q3 2025.
- For Q3 2025, EBIAT rose 4.14% year-over-year to -$35.5 million; the TTM value through Sep 2025 reached -$120.7 million, up 28.26%, while the annual FY2024 figure was -$119.0 million, 56.91% up from the prior year.
- EBIAT reached -$35.5 million in Q3 2025 per NKTR's latest filing, up from -$41.6 million in the prior quarter.
- Across five years, EBIAT topped out at $7.3 million in Q4 2024 and bottomed at -$159.1 million in Q2 2022.
- Average EBIAT over 5 years is -$74.5 million, with a median of -$52.4 million recorded in 2024.
- Peak YoY movement for EBIAT: tumbled 56.9% in 2021, then surged 117.26% in 2024.
- A 5-year view of EBIAT shows it stood at -$145.6 million in 2021, then surged by 59.02% to -$59.7 million in 2022, then rose by 29.5% to -$42.1 million in 2023, then skyrocketed by 117.26% to $7.3 million in 2024, then crashed by 589.22% to -$35.5 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$35.5 million in Q3 2025, -$41.6 million in Q2 2025, and -$50.9 million in Q1 2025.